The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

American Health Packaging is initiating a recall to the RETAIL LEVEL for AHP Buprenorphine Sublingual Tablets (C-III) 2 mg 30UD; carton NDC#: 60687-481-21, (Individual Dose NDC: 60687-481-11).

AHP received a customer complaint reporting receipt of one carton bearing an outer front label for Sildenafil Tablets, USP, 20 mg (NDC 60687-788-21) in place of the expected Buprenorphine Sublingual Tablets, 2 mg (NDC 60687-481-21). The tablets inside the mislabeled carton were confirmed to be Buprenorphine Sublingual Tablets, 2 mg (NDC 60687-481-11).

Buprenorphine is indicated for the treatment of opioid dependence and are preferred for induction. Buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support.

PRODUCT: Buprenorphine Sublingual Tablets 2 mg 30UD

NDC NUMBER: Carton: 60687-481-21
Individual Dose: 60687-481-11

LOT NUMBER: 1030023

EXPIRATION DATE: 06/30/2027

SHIP DATES: 05/04/2026 to 08/03/2026